Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix) or life threatening disease. If there is a history of prior malignancies or life threatening diseases, the patient must be disease free for at least 5 years.
Subjects must not have had prior systemic therapy except for localized emergency radiation to sites of life-threatening or function-threatening disease and/or no more than 1 cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (as per P9641, A3961, ANBL0531, or similar) prior to determination of MYCN amplification status and histology.
Other serious or life-threatening conditions deemed unacceptable by the principal investigator
History of life threatening or recurrent thrombosis/embolism; patients may participate if they are on anticoagulation during the treatment
Evidence of immediate life-threatening disease or a life expectancy of less than 3 months
Uncontrolled active life-threatening infection.
Known intolerance to or life threatening side effects resulting from prior checkpoint inhibitor therapy
Active life-threatening infection
Patient has malignancy or life-threatening systemic disease or a history of advanced, serious, life-threatening malignancy/disease within the last 5 years, except very low-risk prostate cancer
Active life-threatening infection
Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeon
Active life-threatening infection
Patients with an impending, life-threatening cerebral herniation syndrome, based on the assessment of the study neurosurgeons or their designate
Has an uncontrolled, life-threatening active infection
No clinical evidence of life-threatening infection
Patients with untreated or uncontrolled life-threatening infection
Active life-threatening infection
Patients must not have untreated or uncontrolled life-threatening infection
No life threatening parenchymal disease or rapidly progressing disease warranting cytotoxic chemotherapy
Active life-threatening infection
Unstable or life-threatening arrhythmia
Patients with other conditions not related to CMV infection (e.g. uncontrolled bacterial sepsis or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T-cell infusion.
Active life-threatening infection
Significant extrahepatic disease representing an imminent life-threatening outcome
Active life-threatening cancer requiring treatment other than ALL
MATCHED RELATED DONOR: No history of life-threatening opportunistic infection
HAPLOIDENTICAL RELATED DONOR: No history of life-threatening opportunistic infection
Active life-threatening infection
No life- or organ-threatening manifestations of MCD
Active life-threatening infection
Severe life, threatening infection
Severe life, threatening infection
Significant extrahepatic disease representing an imminent life-threatening outcome
HAPLOIDENTICAL RELATED DONOR: No history of life-threatening opportunistic infections
Active life-threatening infection
Significant extrahepatic disease representing an imminent life-threatening outcome
Significant extrahepatic disease representing an imminent life threatening outcome
Patients with an uncontrolled life-threatening infection
Patients with life-threatening condition or complication other than their basic condition
Known life-threatening systemic disease
Evidence of immediately life-threatening disease, progressively fatal disease, or life expectancy of 3 months or less (eg, moribund or with shock unresponsive to fluid replacement)
Other life-threatening illness that is expected to impact life expectancy within 3 years
Unstable or life-threatening arrhythmia
Presence of any life-threatening co-morbidity
Presence of any life-threatening co-morbidity
Active life-threatening infection
Immediately life-threatening, severe complications of leukemia.
Patients must not have untreated or uncontrolled life-threatening infection
Participants must not have life-threatening co-morbidities
Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
Active life-threatening infection
Any subject who has a life-threatening condition that requires high-dose immunosuppressant(s)
Other serious or life-threatening conditions deemed unacceptable by the principal investigator
Patients must not have untreated or uncontrolled life-threatening infection
History of life threatening or recurrent thrombosis/embolism; subjects may participate if they are adequately anticoagulated during the treatment
No untreated or uncontrolled life-threatening infection
Severe or life-threatening infection within 2 weeks of entry onto the study
Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
Patients with an uncontrolled life-threatening infection
Evidence of immediately life-threatening disease, progressively fatal disease, or life expectancy of 3 months or less.
Uncontrolled life-threatening infections
Any life-threatening condition that could affect protocol compliance.
Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
Subject has an active, uncontrolled systemic infection considered opportunistic, life-threatening, or clinically significant at the time of treatment.
are eligible for any standard therapy known to be life prolonging or life saving
Uncontrolled, life-threatening infection that is not responding to antimicrobial therapy
Evidence of life-threatening or fulminant CDAD.
Patients must have had no prior systemic therapy except for localized emergency radiation to sites of life-threatening or function-threatening disease and/or no more than 1 cycle of chemotherapy per low- or intermediate-risk neuroblastoma therapy (P9641, A3961, ANBL0531) prior to determination of MYCN amplification and histology
Known severe or life-threatening allergy or intolerance to ATG or cyclosporine/ tacrolimus
History of life threatening or recurrent thrombosis/embolism; patients may participate if they are on anticoagulation during the treatment
Patients with other conditions not related to CMV infection (e.g. uncontrolled bacterial sepsis or invasive fungal infection) which are also life-threatening and which would preclude evaluation of the effects of a T-cell infusion
Subjects must be free of life-threatening illness (e.g., cancer) that would severely limit participation; those with chronic illnesses (e.g., asthma, diabetes) may participate with the permission of their physician
Have current or a history of ventricular or life-threatening arrhythmias or diagnosis
Current metabolic or life-threatening disease
Untreatable life-threatening arrhythmias
Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example:
Acute life threatening infection
